Dive Into Other Topics

Jun 10, 2025

On 19 May 2023, FDA approved Abbvie-Genmab’s EPKINLY, as the first CD20XCD3 bispecific antibody R/R DLBCL treatment in adults.

Jun 06, 2025

Cloud computing in the healthcare industry is growing at an immense pace. Despite some difficulties, the advantages of cloud computing are more compared to disadvantages

Jun 06, 2025

As per the latest assessment by DelveInsight, the global sleep tech devices market was valued at ~USD 17 billion in 2023, growing at a CAGR of 17.31% during the forecast period from 2024 to 2030 to reach ~USD 44 billion by 2030.

Mar 14, 2025

80+ pharma companies are working to assess challenges & seek opportunities that could influence obesity treatment scenario in coming years.

Mar 02, 2025

On September 29, 2023, FDA approved EXXUA, the ER gepirone hydrochloride tablets by Fabre-Kramer, for major depressive disorder treatment.

Feb 12, 2025

Donanemab is a promising new Alzheimer’s disease treatment. Donanemab has the potential to rule the Alzheimer’s disease market.

Feb 12, 2025

Despite facing significant setbacks, companies such as Eli Lilly, BioVie, and others are developing effective Alzheimer's disease treatments.

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...

Feb 06, 2025

Polycythemia vera treatment market is expected to substantially change and it will be dominated by approved products, JAKAFI and BESREMi.

Nov 29, 2024

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.